Tags : Sanofi

Weekly Snapshot

PharmaShots Weekly Snapshots (Apr 12 – 16, 2021)

ThermoFisher to Acquire PPD for ~$17.4B Published: Apr 16, 2021 | Tags: ThermoFisher, Acquire, PPD, ~$17.4B Roche’s Evrysdi (risdiplam) Receives Health Canada’s Approval for Spinal Muscular Atrophy in Adults and Children Published: Apr 16, 2021 | Tags: Roche, Evrysdi (risdiplam), Receives, Health Canada, Approval, Spinal Muscular Atrophy, Adults, Children GSK Discontinues the P-II Trials of […]Read More

Pharma

Sanofi Collaborates with C4XD for an Oral Therapy to Treat

Shots: Sanofi has signed an exclusive worldwide licensing agreement with C4XD worth up to $492.94M million, for C4XD’s oral pre-clinical IL-17A inhibitor program C4XD to receive $8.33M up front and is eligible to receive up to $484.60M as development, regulatory and commercial milestones including $13.09M as pre-clinical milestones along with royalties Sanofi will develop and […]Read More

M&A

Sanofi to Acquire Tidal Therapeutics for ~$470M

Shots: Sanofi to acquire Tidal Therapeutics for $160M up front and ~ $310M following the achievement of certain milestones The acquisition will add Tidal’s innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas With its acquisition, Sanofi will further develop the technology platform to expand its research capabilities in immuno-oncology and […]Read More

Top 20

Top 20 BioPharma Companies based on 2020 Total Revenue

Despite having the global Covid-19 pandemic, the biopharma companies were involved in multiple M&A and licensing deals. The major focus of the year remains the production and distribution of vaccines to combat the COVID-19 globally All of the Biopharma companies on our list are on the front line to combat this global crisis. The top […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshots (Mar 29 – Apr 02, 2021)

Pfizer and BioNTech Report Results of BNT162b2 to Prevent COVID-19 Published: Apr 2, 2021 | Tags: Pfizer and BioNTech, Report, Results, BNT162b2, Prevent, COVID-19 Acceleron Presents Results of Sotatercept in P-II PULSAR Trial for the Treatment of Pulmonary Arterial Hypertension, Published in NEJM Published: Apr 2, 2021 | Tags: Acceleron, Presents, Results, Sotatercept, P-II PULSAR […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshots (Mar 15 – 19, 2021)

Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases Published: Mar 19, 2021 | Tags: Takeda, Collaborates, Anima, Discover, Develop, mRNA Translation Modulators, Neurological Diseases Kiniksa’s Arcalyst (rilonacept) Receives the US FDA’s Approval for the Treatment of Pericarditis Published: Mar 19, 2021 | Tags: Kiniksa, Arcalyst (rilonacept), Receives, US, FDA, […]Read More

Pharma

Sanofi Out Licenses Two Sickle Cell Disease Programs to GBT

Shots: Sanofi to receive ~$353M including $2.25M up front and remaining as development, regulatory and commercial milestones as well as royalties on WW net sales of programs GBT gets exclusive WW rights to two early-stage research programs in SCD. One program pursues a novel anti-sickling mechanism and the other leverages a new approach to reduce […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshots (Mar 08 – 12, 2021)

PhaseBio Signs a Supply Agreement with BioVectra to Support the Development and Commercialization of Bentracimab Published: Mar 12, 2021 | Tags: PhaseBio, Signs, Supply, Agreement, BioVectra, Support,  Development, Commercialization, Bentracimab Takeda Reports NDA Submission of Lanadelumab to the MHLW as a Preventive Treatment for Hereditary Angioedema Attack in Japan Published: Mar 12, 2021 | Tags: […]Read More